BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng LF, Wang F, Zhang L, Yu L, Ye W, Liu ZY, Ying QK, Wu XA, Xu ZK, Zhang FL. Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles. Front Cell Infect Microbiol 2016;6:185. [PMID: 28066721 DOI: 10.3389/fcimb.2016.00185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Li P, Jiang X, Zhang G, Trabucco JT, Raciti D, Smith C, Ringwald M, Marai GE, Arighi C, Shatkay H. Utilizing image and caption information for biomedical document classification. Bioinformatics 2021;37:i468-76. [PMID: 34252939 DOI: 10.1093/bioinformatics/btab331] [Reference Citation Analysis]
2 Ma HW, Ye W, Chen HS, Nie TJ, Cheng LF, Zhang L, Han PJ, Wu XA, Xu ZK, Lei YF, Zhang FL. In-Cell Western Assays to Evaluate Hantaan Virus Replication as a Novel Approach to Screen Antiviral Molecules and Detect Neutralizing Antibody Titers. Front Cell Infect Microbiol 2017;7:269. [PMID: 28676847 DOI: 10.3389/fcimb.2017.00269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
3 Dong Y, Ma T, Zhang X, Ying Q, Han M, Zhang M, Yang R, Li Y, Wang F, Liu R, Wu X. Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into Hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection. J Med Microbiol 2019;68:480-92. [PMID: 30657443 DOI: 10.1099/jmm.0.000897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
4 Bongard N, Lapuente D, Windmann S, Dittmer U, Tenbusch M, Bayer W. Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors. Retrovirology 2017;14:28. [PMID: 28449719 DOI: 10.1186/s12977-017-0352-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
5 Lei X, Cai X, Yang Y. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines. Expert Rev Vaccines 2020;19:235-46. [PMID: 32133886 DOI: 10.1080/14760584.2020.1738227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Liu R, Ma H, Shu J, Zhang Q, Han M, Liu Z, Jin X, Zhang F, Wu X. Vaccines and Therapeutics Against Hantaviruses. Front Microbiol 2019;10:2989. [PMID: 32082263 DOI: 10.3389/fmicb.2019.02989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
7 Gogesch P, Schülke S, Scheurer S, Mühlebach MD, Waibler Z. Modular MLV-VLPs co-displaying ovalbumin peptides and GM-CSF effectively induce expansion of CD11b+ APC and antigen-specific T cell responses in vitro. Mol Immunol 2018;101:19-28. [PMID: 29852456 DOI: 10.1016/j.molimm.2018.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
8 Jiang DB, Zhang JP, Cheng LF, Zhang GW, Li Y, Li ZC, Lu ZH, Zhang ZX, Lu YC, Zheng LH, Zhang FL, Yang K. Hantavirus Gc induces long-term immune protection via LAMP-targeting DNA vaccine strategy. Antiviral Res 2018;150:174-82. [PMID: 29273568 DOI: 10.1016/j.antiviral.2017.12.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]